INTIVA BioPharma is proceeding with pre-clinical and clinical drug development activities, under FDA protocol for pharmaceuticals that include cannabinoids.

DENVER, CO, USA, July 12, 2017 /EINPresswire.com/ -- INTIVA BioPharma Inc. (“BioPharma”) announced today that New York City-based, Alain Bankier has joined the Company as Chief Strategy Officer. Mr. Bankier is also a Director of BioPharma.

Mr. Bankier is an entrepreneur and an active early stage investor. He has invested in a variety of companies in the legal cannabis, technology, and food/tech industries. As an active board member and advisor to a number of companies, he has been instrumental in helping companies achieve their business milestones and liquidity events.

Mr. Bankier has an extensive involvement in the cannabis industry. He is a co-founder and Managing Partner of VSTechVentures, a partnership that provides legal, tech and business advisory help to early stage and high growth companies in the legal cannabis industry.

Mr. Bankier is also the co-founder of the New York Angels, one of the leading early-stage investment groups in the US and he is also a prominent member of ArcView, the national cannabis industry investing organization. He has invested in a variety of publicly-traded and privately-held legal cannabis companies, which include companies involved in cultivation, processing, dispensaries, technology and ancillary businesses.

Until 2014, Mr. Bankier was a shareholder and Co-President/CEO of The Manischewitz Company. He acquired the Manischewitz Company in 2008, through a merger with his operating company SFG. SFG’s strategy was to build value by acquiring companies that were in need of restructuring due to operational, branding or financial issues (and usually all three) and implementing an operational and financial “turnaround” and growth plan.

Prior to his career in the food industry, Mr. Bankier was a founder of an international boutique investment bank, which he sold to BNPParibas in 1989 and where he remained as the Co-Head of Corporate Finance/Mergers and Acquisitions North Americas until 2001.

Mr. Bankier has a BS from the Wharton School and a BA from the University of Pennsylvania. He also has an MBA from NYU Stern and from HEC Paris.

In commenting on Mr. Bankier joining Intiva BioPharma joining the Company’s management team, Jeffrey Friedland, CEO stated, “We’re delighted that Alain has joined our management team. As Intiva BioPharma is rapidly proceeding with its cannabinoid-based drug development activites, Alain will provide an invaluable role in determining BioPharma’s short-term and long-term strategies.”

In commenting on his becoming Chief Strategy Officer, Bankier commented, “Since its inception, I have had the opportunity to view first-hand the exciting progress that BioPharma has made, and I look forward to working with this strong management team to help plan our direction for the future…..”

About INTIVA BioPharma Inc.

INTIVA BioPharma is proceeding with pre-clinical and clinical drug development activities, in accordance with U.S. Food and Drug Administration ("FDA") protocols, for a number of pharmaceutical formulations that include cannabinoids.

Currently, the Company is proceeding with early-stage drug development activities for six different medical conditions or disorders. For each of these, BioPharma has either licensed the intellectual property or filed U.S. provisional patent applications.

BioPharma’s drug development strategy consists of:

The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;

Conducting “freedom to operate” investigations on these conditions;

The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;

Identifying the regulatory pathway with the U.S. Food and Drug Administration (FDA); and

Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).

INTIVA Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:

Jeffrey Friedland
Chief Executive Officer
INTIVA BioPharma Inc.
Tel. 1-800-497-2915
Email IntivaBioPharma@intiva.us
Website www.INTIVABioPharma.com

Jeffrey Friedland
INTIVA BioPharma Inc.
email us here
1-800-497-2915

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.